Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,766 GBX | +2.11% | -0.45% | +21.81% |
09:35am | GSK Regarding Ruling By Delaware State Court On Zantac Litigation Will Immediately Seek Appeal | RE |
May. 31 | US FDA approves Moderna's RSV vaccine, its second marketed product | RE |
Sales 2024 * | 31.64B 40.31B | Sales 2025 * | 33.59B 42.8B | Capitalization | 72.04B 91.78B |
---|---|---|---|---|---|
Net income 2024 * | 5.56B 7.08B | Net income 2025 * | 6.5B 8.29B | EV / Sales 2024 * | 2.67 x |
Net Debt 2024 * | 12.39B 15.79B | Net Debt 2025 * | 8.95B 11.4B | EV / Sales 2025 * | 2.41 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
11.1
x | Employees | 70,212 |
Yield 2024 * |
3.45% | Yield 2025 * |
3.57% | Free-Float | 94.54% |
Latest transcript on GSK plc
1 day | +2.11% | ||
1 week | -0.45% | ||
1 month | +5.59% | ||
3 months | +6.12% | ||
6 months | +24.45% | ||
Current year | +21.81% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 17 M€ | +6.09% | - | |
2.51% | 7 M€ | +9.96% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1,766 | +2.11% | 17,477,210 |
24-05-30 | 1,730 | -0.94% | 8,017,940 |
24-05-29 | 1,746 | +0.37% | 10,002,350 |
24-05-28 | 1,740 | -1.94% | 4,684,441 |
24-05-24 | 1,774 | -0.20% | 4,163,301 |
Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.81% | 91.66B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- GSK Stock